Administering two doses of NVX-CoV2373 (Novavax) vaccine lowers the occurrence of virologically confirmed symptomatic mild, moderate, or severe COVID-19 in healthy adults, according to data from the 2019nCoV-302* study.
The odds of severe COVID-19 illness, hospitalization, and long COVID-19 were significantly reduced by more than half after two doses of vaccines compared with those unvaccinated, reveal data from a real-world study. Even if fully vaccinated people were infected, they were twice as likely to be completely asymptomatic than unvaccinated ones.
The antiviral monoclonal antibodies casirivimab-imdevimab appear to reduce the risk of hospitalization in patients with nonsevere COVID-19, as do bamlanivimab, bamlanivimab-etesevimab, and sotrovimab, according to the results of a systematic review and meta-analysis.
A manikin study has shown that use of the standard face shield is not enough to protect against droplet dispersion during oropharyngeal COVID-19 swabs, but the SG Shield results in significant reduction of droplet contamination to the swab provider’s face and chest.
Cardiac manifestations, such as acute myocardial infarction (AMI) and myocarditis, after vaccination for the coronavirus disease 2019 (COVID-19) are more common in men, according to a recent Singapore study. AMI is more likely to arise after the first shot, while myocarditis becomes more common after the second dose.
Oteseconazole (VT-1161), a novel investigational fungal CYP51 inhibitor, outdid fluconazole/placebo for managing acute and recurrent* vulvovaginal candidiasis (VVC), according to data from the phase III ultraVIOLET trial.
A large international database study has shown that children and adolescents with cancer have an elevated risk of severe or critical disease if infected with COVID-19. Furthermore, about half the patients receiving cancer therapy experienced modifications to their treatment regimens.